Is FODZYME® clinically proven?Updated a month ago

FODZYME® is supported by in-vitro and clinical studies that demonstrate its effectiveness in breaking down FODMAPs and improving digestive comfort.

A peer-reviewed study published in Gastro Hep Advances evaluated FODZYME® using SHIME®, a scientifically validated model of the human gut [1]. The study found that FODZYME® rapidly breaks down fructans, with 90% degradation (equivalent to 6 garlic cloves) occurring within 30 minutes. Additionally, 70% of the released fructose was absorbed during simulated small intestinal transit. The research also demonstrated a significant reduction in microbial gas production, which may contribute to digestive relief, while maintaining a balanced production of short-chain fatty acids (SCFAs), essential for gut health. This study was recognized as a Top 15 Basic Science Research by the American Gastroenterology Association (AGA) in 2023.

A real-world, self-controlled case series assessed FODZYME®'s effectiveness in individuals with a history of Irritable Bowel Syndrome (IBS) [2]. Among 131 participants who completed the 4-week study, 93 reported a history of IBS. Results showed that 73.1% of participants experienced overall symptom improvement, 70.0% reported a decrease in bloating frequency, and 76.3% saw fewer daily disruptions due to digestive issues. Additionally, 64.5% experienced improvements in food avoidance behaviors, and 57.0% reported better mental well-being.

These findings provide strong support for FODZYME®’s potential to help individuals with digestive sensitivities enjoy a broader diet while managing symptoms. We are committed to continuously expanding the scientific and clinical evidence behind FODZYME® to further validate its effectiveness.

References

1. Ochoa KC, Samant S, Liu A, et al. In Vitro Efficacy of Targeted Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Enzymatic Digestion in a High-Fidelity Simulated Gastrointestinal Environment. Gastro Hep Advances. 2022;2(3):283-290. doi:https://doi.org/10.1016/j.gastha.2022.10.011‌
2. Kaye A, Meyers S, Hachuel D, Wells J, Wallach T, Thor S. S818 Fodzyme at Its Finest: A Case Series Exploring a New Option for IBS Patients. The American Journal of Gastroenterology. 2024;119(10S):S561-S561. doi:https://doi.org/10.14309/01.ajg.0001032640.36029.68